COMPARISON OF THE EFFECTIVENESS OF GENE THERAPY AND STANDARD CONSERVATIVE THERAPY FOR PATIENTS WITH CHRONIC LOWER LIMB ISCHEMIA DUE TO ATHEROSCLEROSIS

Abstract

OBJECTIVE. The objective is to compare the effectiveness of standard conservative therapy (SCT) and the complex therapy with preparation based on VEGF165 gene in patients with the stage II of chronic lower limb ischemia according to Fontaine classification during 5 years.MATERIAL AND METHODS. In total, 92 patients were enrolled in the study. Patients were divided into 2 groups (n=46 for each group). In the first group, patients got only conservative therapy and in the second group, patients were received SCT in combination with injection of gene drug into the ischemic limb muscles.RESULTS. The using of gene therapy in complex management in patients with the stage II of chronic lower limb ischemia led to significant increasing of the average pain-free walking distance (up to 500 %) (p=0.007). In addition, there were 65 % of the patients in the second group obtaining a significant and moderate improvement. By contrast, there was only 3 % of cases in the first group having similar results with standard therapy. Only gene therapy has statistically significance in the secondary parameters of treatment efficiency.CONCLUSION. The efficiency of complex treatment with gene therapy in patients with the stage II of ch ronic lower limb ischemia for 5 years exceeds significantly the efficiency of standard conservative therapy.

Keywords

• peripheral atherosclerosis
• conservative treatment
• gene therapy
• plasmid-based vegf165 gene therapy
• «neovasculge